STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Theravance Biopharma to Participate in an Upcoming Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the 7th Annual Evercore HealthCONx Conference. The company will engage in a Fireside Chat on Tuesday, December 3 at 11:15 am EST, alongside hosting in-person meetings with the investment community. The event will be accessible via webcast on Theravance.com under the Investors section, with a replay available for 30 days following the presentation.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

DUBLIN, Nov. 20, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am EST (8:15 am PST/4:15 pm GMT) and will be hosting in-person meetings with the investment community at the conference. 

Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302311022.html

SOURCE Theravance Biopharma, Inc.

FAQ

When is Theravance Biopharma (TBPH) presenting at the Evercore HealthCONx Conference?

Theravance Biopharma will present on Tuesday, December 3 at 11:15 am EST (8:15 am PST/4:15 pm GMT).

How can investors access TBPH's Evercore HealthCONx Conference presentation?

Investors can access the webcast through Theravance.com, under the Investors section, Events and Presentations.

How long will TBPH's Evercore Conference presentation replay be available?

The webcast replay will be archived on Theravance's website for 30 days after the event.

What type of presentation will TBPH give at the Evercore Conference?

TBPH will participate in a Fireside Chat format presentation and host in-person meetings with the investment community.
Theravance Bioph

NASDAQ:TBPH

TBPH Rankings

TBPH Latest News

TBPH Latest SEC Filings

TBPH Stock Data

933.89M
48.49M
4.37%
92.14%
8.86%
Biotechnology
Pharmaceutical Preparations
Link
United States
GEORGE TOWN, GRAND CAYMAN